• Multiple myeloma (MM) is a cancer of terminally differentiated plasma B cells that originates in the hematopoietic bone marrow and accounts for 15%-20% of all hematologic malignancies ( 1 , 2 ). (snmjournals.org)
  • Autologous hematopoietic stem cell transplantation (auto-SCT) is the recommended treatment for responding patients with multiple myeloma (MM). However, we do not know the risk factors influencing long-term survival without progression after auto-SCT. (bvsalud.org)
  • The patient received allogeneic hematopoietic stem cell transplantation (allo-HSCT) from human leukocyte antigen (HLA) matched related donor. (bvsalud.org)
  • Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. (medscape.com)
  • 30,000 patients with blood-related malignancies receive HDC, which, if the response is satisfactory, could subsequently be followed by hematopoietic stem cell transplantation (HSCT). (bdbiosciences.com)
  • CD34, a transmembrane phosphoglycoprotein, is present on immature hematopoietic precursor cells and all hematopoietic colony-forming cells in bone marrow and blood, including unipotent and pluripotent progenitor cells. (bdbiosciences.com)
  • 4 CD34 expression is historically related to hematopoietic cells and it is considered as the marker of HSCs. (bdbiosciences.com)
  • For many hematopoietic malignancies, collection and infusion of CD34+ hematopoietic stem/progenitor cells following chemotherapy is critical. (bdbiosciences.com)
  • The BD ® Stem Cell Enumeration (SCE) Kit provides simultaneous enumeration of viable dual-positive CD45+/CD34+ hematopoietic stem cell populations in CD34+ absolute counts (cells/µL) as well as the percentage of the total viable leucocyte count that is CD34+ (%CD34). (bdbiosciences.com)
  • Though untreated the disease is uniformly fatal, newer advances in treatment like autologous hematopoietic stem cell transplantation, mini-transplants and advances in chemotherapy have improved the quality of life and increased survival (Gupta et al. (journalcra.com)
  • Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment for hematologic malignancies such as multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). (bloodline.net)
  • Hematopoietic cell transplantation has become a cornerstone in the management of patients with lymphoma. (bloodline.net)
  • Only patients who were not treated with autologous or allogeneic hematopoietic stem cell transplant were included. (jcancer.org)
  • Background: The mainstay of therapy for newly diagnosed multiple myeloma patients remains systemic chemotherapy. (drugpatentwatch.com)
  • Methods: Myeloma XI is a large, phase III randomised trial in-which lenalidomide was used at induction and maintenance, in transplant eligible (TE) and non-eligible (TNE) newly diagnosed patients (NCT01554852). (nyu.edu)
  • PURPOSE/OBJECTIVE:Chromosome 1 (chr1) copy number abnormalities (CNAs) and structural variants (SV) are frequent in newly diagnosed multiple myeloma (NDMM) and associate with a heterogeneous impact on outcome the drivers of which are largely unknown. (nyu.edu)
  • The study of 668 patients with newly-diagnosed multiple myeloma compared treatment with two courses of Celgene's Alkeran (melphalan) to the combination of Alkeran and Celgene's Thalomid brand of thalidomide alongside autologous stem cell transplantation. (pharmatimes.com)
  • 2002). The three drug regimens that contain bortezomib (proteasome inhibitor), thalidomide (immunomodulator) and dexamethasone (VTD) is highly effective in newly diagnosed myeloma (Richardson et al. (journalcra.com)
  • B.D. Sharma PGIMS, Rohtak on all newly diagnosed multiple myeloma patients attending the haematology department, wards and OPD from Feb 2016 to Nov 2017. (journalcra.com)
  • All newly diagnosed cases who fulfilled the diagnostic criteria of multiple myeloma by IMWG were included in study. (journalcra.com)
  • The tumor was successfully treated with chemotherapy, but 3 years later she was diagnosed with T-cell lymphoblastic lymphoma. (bvsalud.org)
  • SummaryDiffuse large B‑cell lymphoma (DLBCL) comprises 30-40% of non-Hodgkin's lymphoma. (deepdyve.com)
  • HDC with transplant is now standard therapy in multiple myeloma, acute myeloid leukemia in first remission, and intermediate-grade non-Hodgkin's lymphoma. (bdbiosciences.com)
  • Waldenström's macroglobulinemia is a slow-growing form of non-Hodgkin lymphoma that originates in white blood cells known as B lymphocytes. (sciencedaily.com)
  • The discovery of a genetic signature for Waldenström's will enable doctors to definitively determine which patients have the disease and not a similar condition such as other forms of lymphoma or multiple myeloma, Treon says. (sciencedaily.com)
  • The use of autologous transplant in Hodgkin's and non-Hodgkin's lymphoma has significantly improved the survivals of patients with relapsed disease. (bloodline.net)
  • Dr. Alfred Garfall explains how the work began in leukemia and lymphoma and is now being tested in multiple myeloma. (healthtree.org)
  • Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. (medscape.com)
  • Mantle cell lymphoma (MCL) is recognized in the Revised European-American Lymphoma and World Health Organization classifications as a distinct clinicopathologic entity. (medscape.com)
  • it was frequently categorized as diffuse small-cleaved cell lymphoma (by the International Working Formulation) or centrocytic lymphoma (by the Kiel classification). (medscape.com)
  • Future work will explore additional MM cell lines with heterogeneous LAT1 expression and response to melphalan therapy. (snmjournals.org)
  • Allogeneic stem cell transplantation (SCT) results in a high percentage of complete remissions, but it can be associated with significant treatment-related mortality, which has been primarily attributed to conventional myeloablative transplant regimens. (drugpatentwatch.com)
  • An allogeneic transplant uses someone else's stem cells. (medlineplus.gov)
  • It is a strategy that hails from the same philosophy as the allo (donor) transplant - embolden the immune system and arm it with enough power to fight off the myeloma. (healthtree.org)
  • Dr. Garfall of the University of Pennsylvania describes how CAR T cell therapy works and how the first target of CD19 was used in combination with autologous stem cell transplant. (healthtree.org)
  • Used for patients who had already relapsed after transplant in a clinical trial of 10 patients, he shares the mixed results to date with one del 17 patient that never achieved complete response (CR) in the first transplant, achieving it in the second transplant with the addition of CAR T cell therapy. (healthtree.org)
  • In the last decade, the availability of autologous stem cell transplantation and combination therapies consisting of immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics has improved median 5-y survival from 34.6% in 2004 to 49.6% in 2013 ( 3 , 4 ). (snmjournals.org)
  • For Treatment we use different, state of the art therapy Options as Immune Therapy, Chemotherapy and the treatment with targeted therapies. (uniklinikum-dresden.de)
  • There is a critical need for more effective therapies in multiple myeloma (MM) since all patients eventually relapse following front-line treatment. (touchoncology.com)
  • The present invention provides stem cells enriched with healthy functional mitochondria, and therapeutic methods utilizing such cells for the alleviation of debilitating conditions, including aging, and age-related diseases as well as the debilitating effects of anti-cancer therapies in subjects in need thereof. (justia.com)
  • Various changes in the field over the past decade, including the frequent use of tandem aHSCT in MM, the advent of novel therapies for the treatment of MM and NHL, plus the addition of new stem cell mobilization techniques, have led to the need to reassess current stem cell mobilization strategies. (bloodline.net)
  • Aplastic anemia (AA), the myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) are rare diseases that all result in bone marrow failure-the ineffective formation of circulating blood cells-leading to anemia, bleeding, infection, and death in many cases, even with modern therapies. (bloodline.net)
  • Dr. Cho's laboratory is investigating novel therapies for multiple myeloma in two areas. (themmrf.org)
  • First, they are investigating immunologic therapies with a focus on using cutting edge genomic and immunologic assays to map the interaction between myeloma and the immune system in the tumor microenvironment. (themmrf.org)
  • Several drug therapies are valuable in the treatment of symptomatic MM. Clinicians treat many patients with high-dose therapy and peripheral blood or bone marrow stem cell transplantation. (medscape.com)
  • Dimeo F, Schwartz S, Fietz T, Wanjura T, Boning D, Thiel E: Effects of endurance training on the physical performance of patients with hematological malignancies during chemotherapy. (karger.com)
  • Prior chemotherapy is found to be an independent risk factor for the development of secondary malignancies, which are usually associated with a worse prognosis. (bvsalud.org)
  • SummaryChimeric antigen receptor T cells (CAR-T cells) are a novel form of cellular immunotherapy for patients with hematologic and oncologic malignancies. (deepdyve.com)
  • The main causes of death included infectious complications (n = 9), relapse with subsequent chemotherapy resistance (n = 7), steroid-resistant GvHD (n = 4) and other causes (n = 2). (bvsalud.org)
  • Previous studies have shown that children with acute myeloid leukemia (AML) who developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell transplantation (allo-SCT). (shengsci.com)
  • Chemotherapy was resumed without any subsequent relapse of hepatic enzyme elevation. (journaltocs.ac.uk)
  • Bong I, Ng CC, Baharuddin P, Zakaria Z: MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy. (karger.com)
  • Multiple myeloma (MM) is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • ABSTRACT Multiple myeloma (MM) is a systemic malignancy of pathologic plasma cells that is treat able with chemotherapeutic agents and irradiation, but rarely curable. (who.int)
  • Although partial remissions of up to 60% are obtained with conventional regimens, multiple myeloma is essentially an incurable disease with a median survival of approximately 30 months. (drugpatentwatch.com)
  • Bulky symptomatic disease may require combination regimens, such as chemotherapy. (medscape.com)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • NCCN clinical practice guidelines in oncology: multiple myeloma. (medlineplus.gov)
  • We'd like to thank today's episode sponsor Takeda Oncology for their support of Myeloma Crowd Radio and myeloma patients as a whole. (healthtree.org)
  • Here we present an analysis of SPM incidence and profile the SPM type to determine the impact of autologous stem cell transplantation (ASCT) and lenalidomide exposure in 4358 patients treated on study. (nyu.edu)
  • Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
  • We know that surgery prolongs survival in many cancers from multiple studies. (respectfulinsolence.com)
  • Indeed, as I have pointed out before, this study appears almost intentionally designed to leave out the very types of cancers for which chemotherapy provides the most survival benefit. (respectfulinsolence.com)
  • Of all the other cancers, multiple myeloma causes this complication the most. (webmd.com)
  • There is a need for further investigation into the effects of and guidelines for exercise interventions (especially strength training) in this population of patients, particularly among cancer patients who are undergoing or have undergone chemotherapy or radiation treatments. (karger.com)
  • Dimeo FC, Tilmann MH, Bertz H, Kanz L, Mertelsmann R, Keul J: Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. (karger.com)
  • Dolan LB, Gelmon K, Courneya KS, Mackey JR, Segal RJ, Lane K, Reid RD, McKenzie DC: Hemoglobin and aerobic fitness changes with supervised exercise training in breast cancer patients receiving chemotherapy. (karger.com)
  • Non-melanoma skin cancer incidence was highest in patients receiving lenalidomide maintenance, particularly in TNE patients, where squamous cell carcinoma and basal cell carcinoma were diagnosed in 5.5% and 2.6% of patients, respectively. (nyu.edu)
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
  • Adding thalidomide to a standard regimen of high-dose chemotherapy in patients with the cancer multiple myeloma improved complete responses but did not give any advantage in five-year survival, according to a study published in the New England Journal of Medicine (March 9). (pharmatimes.com)
  • Stem cell transplantation is performed after high-dose chemotherapy (HDC) to restore a cancer patient's blood and immune cell production capacity. (bdbiosciences.com)
  • As the cancer cells grow in the bone marrow, you may have bone pain, most often in the ribs or back. (medlineplus.gov)
  • The cancer cells can weaken bones. (medlineplus.gov)
  • The present invention relates to stem cells enriched with functional mitochondria, and therapeutic methods utilizing such cells to diminish the debilitating effects of various conditions, including aging and age-related diseases as well as the debilitating effects of anti-cancer therapy treatments. (justia.com)
  • Also, it uses 5 year survival exclusively, completely neglecting that chemotherapy can prevent late relapses, and there were also a lot of inconsistencies and omissions in that leukemias were not included, while leukemia is one type of cancer against which chemotherapy is most efficacious. (respectfulinsolence.com)
  • Hearn Jay Cho is an Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai and an Attending Physician with the Multiple Myeloma Service at the Mt. Sinai Tisch Cancer Institute. (themmrf.org)
  • Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (merckmanuals.com)
  • RÉSUMÉ Le myélome multiple est un cancer systémique caractérisé par des cellules plasmatiques anormales, qui peut être traité par des agents chimiothérapeutiques et par irradiation, mais qui est rarement curable. (who.int)
  • Multiple myeloma (MM) is a cancer of the The largest series, 23 patients with lepto- plasma cells. (who.int)
  • Enhancement of human erythroid progenitor cell growth by media conditioned by a human t-lymphocyte line. (shengsci.com)
  • 2 Evaluation of harvest adequacy requires the use of reliable progenitor cell assays and this is usually achieved by CD34 cell counting using flow cytometry. (bdbiosciences.com)
  • Flow cytometric applications for CD34+ cell identification and enumeration provide a rapid, quantitative and reproducible method to evaluate the progenitor cell population. (bdbiosciences.com)
  • Moreover, she underwent effective double transplantations and was eventually found to be cured despite accompanying complications. (bvsalud.org)
  • Complications such as renal failure, infections, anemia, lytic bone lesions and amyloidosis lead to morbidity as well as mortality (UK myeloma forum, 2001). (journalcra.com)
  • Also, myeloma complications like kidney damage, frequent infections, high blood calcium, and more may change how well your brain works. (webmd.com)
  • The cer is about 2%-5% and as high as 26% in most common complications include renal small-cell lung carcinoma [ 5 ]. (who.int)
  • These proteins either arise from proteins expressed by cells at the deposition site (localized), or they precipitate systemically after production at a local site (systemic). (medscape.com)
  • SummaryChimeric antigen receptor (CAR) T cells are genetically engineered cells containing fusion proteins combining an extracellular epitope-specific binding domain, a transmembrane and signaling domains of the T cell receptor. (deepdyve.com)
  • Plasma cells help your body fight infection by producing proteins called antibodies . (medlineplus.gov)
  • They demonstrated that type I MAGE plays a critical role in conferring resistance to chemotherapy and inhibition of apoptosis in myeloma cells through regulation of Bcl-2 family proteins and the tumor suppressor p53. (themmrf.org)
  • Myeloma cells produce excess abnormal proteins, called paraproteins, in the bone marrow that can cause your blood to become so thick that it flows sluggishly in your body, a condition called hyperviscosity. (webmd.com)
  • Abnormal proteins from myeloma cells can also damage the kidneys. (webmd.com)
  • Training CAR T cells to seek and destroy specific proteins on the surface of multiple myeloma cells (and the cells themselves) are an exciting new area of study. (healthtree.org)
  • When DILI is suspected during chemotherapy, exclusion of viral hepatitis is mandatory, which can be achieved by measuring markers of hepatitis viruses, including HEV, and examining the patient's detailed medical history. (journaltocs.ac.uk)
  • Donor immunization with myeloma Id in the setting of a non-myeloablative allogeneic SCT may represent a novel strategy for the treatment of multiple myeloma. (drugpatentwatch.com)
  • To determine the treatment-related morbidity and mortality of allogeneic stem cell transplantation using a non-myeloablative conditioning regimen in multiple myeloma. (drugpatentwatch.com)
  • The latter drug was approved for another haematological disease, myelodysplastic syndromes - in December 2005, and has been fast-tracked as a multiple myeloma treatment by the US Food and Drug Administration (FDA). (pharmatimes.com)
  • In 2005, the FDA issued an approvable letter for Thalomid in the treatment of multiple myeloma, asking for additional information on the drug. (pharmatimes.com)
  • Plasma cell neoplasms (including multiple myeloma) treatment (PDQ) - health professional version. (medlineplus.gov)
  • WO 2016/135723 to the present inventors discloses mammalian bone marrow cells enriched with mitochondria for treatment of mitochondrial diseases. (justia.com)
  • Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San MJ: Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. (karger.com)
  • Dr. Cho is responsible for developing the MMRF's clinical research strategy and accelerating drug development programs, as well as for leading the Multiple Myeloma Research Consortium (MMRC), a group of 25 leading research centers dedicated to researching and advancing treatment options for multiple myeloma patients. (themmrf.org)
  • These mental health issues may be due to living with the illness or health problems that you may get because of myeloma medicines or treatment. (webmd.com)
  • Myeloma and treatment for myeloma can weaken your immunity , making the body prone to many infections. (webmd.com)
  • To determine whether antigen-specific immunity, induced in the stem cell donor, can be passively transferred to the allogeneic SCT recipient in the setting of a non-myeloablative conditioning regimen. (drugpatentwatch.com)
  • Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. (shengsci.com)
  • The discovery was made by sequencing the genome of tumor cells in Waldenström's patients, reading the cells' DNA letter by letter, and seeing where it differed from that of the patients' normal cells. (sciencedaily.com)
  • We found that tumor cells in 90 percent of the patients we tested contained a single point mutation, an error in one of the bases that make up the 'rungs' of the DNA helix," says Steven Treon, MD, PhD, who led the research with his Dana-Farber colleague Zachary Hunter. (sciencedaily.com)
  • In subsequent experiments, when we treated the tumor cells with drugs that target the pathway activated by the mutated gene, the cells underwent apoptosis, or programmed cell death. (sciencedaily.com)
  • These results suggest that new, effective treatments that target the tumor cells directly are now possible for people with the disease. (sciencedaily.com)
  • For the current research, Treon and his colleagues conducted whole genome sequencing of tumor cells and normal cells from 30 patients with Waldenström's. (sciencedaily.com)
  • In collaboration with Complete Genomics of Mountain View, Calif., researchers "lined up" the sequences of the tumor and non-tumor cells to identify differences. (sciencedaily.com)
  • Ninety percent of the tumor cells had a point mutation in the gene MYD88. (sciencedaily.com)
  • The mutation causes the cells to produce a distorted protein, which switches on the IRAK complex pathway, leading to activation of NF-kB, a protein that is essential for the growth and survival of Waldenström's tumor cells," Treon comments. (sciencedaily.com)
  • When we shut down the pathway by blocking the abnormal protein with drug molecules, the tumor cells entered apoptosis. (sciencedaily.com)
  • 66-year-old female was diagnosed, following persistent cough, with non-operable tumor of her lung with satellite nodules, and chemotherapy was initiated (first Cisplatin and Gemcitabine, and then switched to Tarceva). (doctorsmedicalopinion.com)
  • Response evaluation following the fourth cycle of chemotherapy showed either stability or an initiation of tumor response, but bone scintigraphy that was performed 6 months later revealed an area of increased uptake in the left hemithorax which could be suggestive of a secondary bone lesion. (doctorsmedicalopinion.com)
  • However, due to complex and varied systemic symptoms, including inflammatory storm, sepsis, acute respiratory failure, tachycardia, coagulopathy, and other extrapulmonary organ injuries, she died 19 days after signs due to severe respiratory failure and multiple organ failure. (flu.org.cn)
  • Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
  • Misdiagnosis of acute hepatitis E virus (HEV) infection as drug-induced liver injury (DILI) may lead to discontinuation of effective chemotherapy. (journaltocs.ac.uk)
  • Additional processes in which mitochondria are involved include heat production, storage of calcium ions, calcium signaling, programmed cell death (apoptosis) and cellular proliferation. (justia.com)
  • The intrinsic immune dysfunction in combination with therapy-related immunosuppression leads to an increased risk for infections, which is a hallmark of multiple myeloma (MM) and major cause of mortality [ 1 - 5 ]. (jcancer.org)
  • [ 1 ] First described in 1848, MM is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • Multiple myeloma (MM), a clonal expansion of plasma cells, is characterised by monoclonal protein production, end-organ damage and marked clinical and genetic heterogeneity. (touchoncology.com)
  • 6 Fluorochrome-conjugated monoclonal antibodies directed against CD34 molecule can be used to identify CD34+ cells by flow cytometry. (bdbiosciences.com)
  • Introduction: Multiple myeloma is characterized by proliferation of a clone of plasma cells that manifest by one or more lytic lesions, monoclonal (M) protein in the blood or urine and bone marrow involvement, ( Sirohi and Powles, 2004) having varying presentation and hematological features. (journalcra.com)
  • When abnormal B cells begin to multiply out of control, they produce excessive amounts of a protein called monoclonal immunoglobulin, which causes the blood to thicken and flow less smoothly. (sciencedaily.com)
  • First described in 1848, MM is characterized by a proliferation of malignant plasma cells and a subsequent overabundance of monoclonal paraprotein (M protein). (medscape.com)
  • Mortality due to progressive myeloma was reduced in patients receiving lenalidomide maintenance, noted to be 16.6% compared 22.6% in those observed in TE patients and 32.7% compared to 41.5% in TNE patients. (nyu.edu)
  • Last year, Celgene was forced to discontinue a trial of a thalidomide derivative - Revlimid (lenalidomide) - in multiple myeloma patients after patients developed blood clots. (pharmatimes.com)
  • Malignant plasma cells in meningeal MM out of 2000 patients with bone marrow produce an immunoglobulin, MM, was reported was by Schluterman et al. (who.int)
  • Second, Dr. Cho's group discovered that two of the type I Melanoma Antigen Genes (MAGE), MAGE-A3 and MAGE-C1, are commonly expressed in multiple myeloma and are correlated with progression of disease and proliferation. (themmrf.org)
  • Overview of Plasma Cell Disorders Plasma cell disorders are a diverse group of disorders of unknown etiology characterized by Disproportionate proliferation of a single clone of B cells Presence of a structurally and electrophoretically. (merckmanuals.com)
  • Therefore, this prospective study aimed to investigate the influence of transplanted cells with cluster of differentiation (CD)184+ expression, CD26+ lymphocytes and monocytes, and reconstitution of CD3+ lymphocytes on overall survival (OS) and progression-free survival (PFS) after auto-SCT in MM. Forty-eight patients with MM underwent auto-SCT at our center from 2011 to 2013. (bvsalud.org)
  • Chemotherapy contributes only just over 2% to the five year survival rate and any contribution from radiotherapy can just as easily be explained by other scientific rationales. (respectfulinsolence.com)
  • Known side effects of these approved cellular immunotherapies are cytokine release syndrome, immune-cell associated neurotoxicity syndrome, cytopenias, infections and long-lasting B cell aplasia. (deepdyve.com)
  • As far as we know, this index represents the first attempt to create such an instrument for predicting the occurrence of infections in myeloma patients. (jcancer.org)
  • Saki N, Abroun S, Hajizamani S, Rahim F, Shahjahani M: Association of chromosomal translocation and miRNA expression with the pathogenesis of multiple myeloma. (karger.com)
  • Antibody- and T-cell-based approaches to targeting of B-cell maturation antigen have shown efficacy. (merckmanuals.com)
  • Recent clinical studies have shown that highly immunosuppressive yet non-myeloablative doses of fludarabine-based chemotherapy can result in alloengraftment. (drugpatentwatch.com)
  • Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
  • Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. (shengsci.com)
  • Clinical factors such as a high International Prognostic Index (IPI) or molecular factors as cell of origin (COO) have an influence on the clinical outcome after conventional immunochemotherapy. (deepdyve.com)
  • The clinical manifestations of Waldenström macroglobulinemia result from the presence of the IgM paraprotein and malignant lymphoplasmacytic cell infiltration of the bone marrow and other tissue sites. (medscape.com)
  • The clinical presentation is similar to that of multiple myeloma except that (1) organomegaly is common in Waldenström macroglobulinemia and is uncommon in multiple myeloma and (2) lytic bony disease and renal disease are uncommon in Waldenström macroglobulinemia but are common in multiple myeloma. (medscape.com)
  • Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (merckmanuals.com)
  • G-CSF is a commonly used mobilizing agent for practically all autologous and a majority of allogeneic HSCTs and is known to increase CD34+ concentration. (bdbiosciences.com)
  • Leukemia is a group of clonal diseases derived from a single cell with a genetic alteration in bone marrow or peripheral lymphoid tissue, and each type is determined by the specificity of the source cell. (sld.cu)